• Anthropic Announces Rare Disease Research Claude Grants

    Clinical Research News | Anthropic yesterday announced a focused call for applications for work on rare genetic diseases. Accepted applicants will receive up to $50,000 in Claude credits over six months, with the goal of building a community of researchers looking into how AI can reshape our understanding of rare disease.

    Jul 21, 2026

  • 3 Tips for a Lean and Efficient Clinical Data Management Function

    Clinical Research News | The landscape of clinical data management (CDM) is becoming increasingly complex. As a BCG report notes, sponsors’ expectations are rising. They are looking for greater consistency in speed and quality, better technology, and improved implementations.

    Jul 17, 2026

  • Coming Soon: One-time Treatment for Debilitating Genetic Condition

    Clinical Research News | Patients with hereditary angioedema have reason to be optimistic that regulatory approval of a one-time, in vivo CRISPR gene-editing therapy for the sudden and severe swelling attacks associated with the rare genetic condition could come as early as next year. Lonvoguran ziclumeran (lonvo-z), as it is known, has been under development by Intellia Therapeutics for the past six years.

    Jul 15, 2026

  • AI Eye Imaging Model Could Accelerate Clinical Trials and Drug Development

    Clinical Research News | An experimental artificial intelligence (AI) model called OCTCube-M could help improve patient selection, predict disease progression, and streamline clinical trials by extracting new insights from three-dimensional optical coherence tomography (OCT) eye scans.

    Jul 14, 2026

  • The Scope of Things: Scaling AI Agents In Clinical Trials

    Clinical Research News | Artificial intelligence agents are beginning to reshape clinical trial operations, but sponsors are still hesitating. Raj Indupuri, CEO of eClinical Solutions, joined the latest episode of The Scope of Things, hosted by Deborah Borfitz, to break down the three main obstacles hindering AI adoption: data readiness, governance and trust, and operating model change.

    Jul 9, 2026

  • Insilico Medicine Launches Phase III Trial for AI-Developed Drug

    Clinical Research News | Insilico Medicine is launching a phase III clinical program for rentosertib, its potentially first-in-class oral small-molecule inhibitor of TNIK (TRAF2- and NCK-interacting kinase) for the treatment of idiopathic pulmonary fibrosis (IPF), a progressive, age-related fibrotic lung disease with high unmet medical need. It is the next step in making AI-discovered drugs a reality for patients.

    Jul 8, 2026

  • Follow the Money: Liver Cell-Reprogramming Therapy, Full-Length Dystrophin Trial, Next-Gen Neuroplastogen

    Clinical Research News | cAMPfield is launching a global phase 2b trial for moderate-to-severe ulcerative colitis and a global phase 2 for Crohn’s disease; Gero intends to advance a portfolio of both disease-modifying and aging-slowing programs in parallel; ClearNote Health continues commercial clinical study execution and broader global access; and more.

    Jul 1, 2026

  • Restoring American Leadership in Clinical Trials, University of Texas MD Anderson Joins Global Consortium, Medable’s DDF Agent

    Clinical Research News | The Ellison Medical Institute enters an exclusive license with UniQuest; TrialAssure and Cancer Research UK’s Centre for Drug Development announce new partnership; EndoDNA launches BIOS, a clinical decision-support; and more.

    Jun 30, 2026